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Studies sbow that tbe timing of tbronkiy:ic tberapy is a major 
factor in determining the magnitude rit the mortality reduction 
with tbesc ageots in the treatment of acute myoeardiaI infarc- 
tion (l-3). Although tbe survival benefit from tbrombolysis 
persists with admhdstratioo up to 12 b aber symptom onset, 
the largest t%ect is observed wben treatmeot begins witbin tbe 
litst hour, with attenuation of the treatnmot benefit over time 
(4). These dinieal observations are consistent with animal 
IaagefdeIaysatatls(ages.I%viousinlsrrtiooarhypasssugerS 
was an a&litiortaI risk hwtor for treatment delay. Early tImto- 
baIysIswasasaaciatedwlthhnreraveraIImortaHyrate(e2b, 
559b>4B,9~),Batseaddi~relativoBeaefttrrsnlted~ 
ediir batmeat wits acdemted t-PA wrws sqtokkw (p = 
038).LQ3gerpresmt3tion3ntltreatmeotdel3yswereb3tJl3sso. 





models of acute coronary occlusion, wbiib show that restora- 
tion of arterial patency witbin 1 to 2 h sahages myoeardium 
and pffscfvcs veotriethr limction (5). AIthough many trials 
have shown better improvement in left ventricular function 
and limitatioo of infarct size with very eatiy treattneot (69), 
none of the large mortality trials have achmlly mllected the to 
treatment. They &owed a sign&cant reIation of time to 
randomization to treatment effect (2,10-12), but exchtsion of 
the variable time from randomktion to treatment may bave 
rcstdtcd in a0 imprecise estimate. of the @ortamx of delay. In 
addition the relatiins between patient characteristics and 
delay in seeking treatmeot (preseotation deiay) and deIa: in 
initiating tbrornboIysis after bospkal arrival (treatment jelay) 
bave Lee0 of interest, but Iitnited sample sizes in indiviouaI 
studies bave led to &abibty in the estimate of factors 
associated with these delays (13). 
Using the 41,021 patieots in tlte GUSTO-I trial, we 
examined patient characteristics as they relate to time-to- 
treatment variables and amessed the reIations between time 
to treatment and its major eompooents, preseotatior delay 
aod treatrnett delay, and tbe r&h of death. We also ,xatn- 
ioed the timedepeodcot q ortabty benefit of tre3totettt with 
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accelerated tissue-type plasminogen activator (t-PA) versus 
two streptokinase monotherapies. 
Methods 
Patient popnh~tio~~ The 41,021 patients in GCSTW corn- 
prised our study population. Complete methods of the trial 
have been published (14). In brief, patients were randomized 
to one of four thrombolytk treatments if they presented within 
6 h of symptom onset (minimum duration 20 min), met 
eledrocardiiphic criteria for acute myxirdial infarction 
(~0.1 mV ST elevation in two or more limb leads or ~0.2 mV 
ST elevation in at least two contiguous precordial leads) and 
had no contraindiitions to thrombolysis. 
Time variahks. For this study, three time variables were 
prospectively defined: time from symptom orrset to hospital 
arrival (presentation delay), time from hospital arrival to 
initiation of thrombolytic therapy (treatment delay), and total 
time from symptom onset to rhromboiytic therapy. The patient 
(or a surrogate if the patient could not communicate) provided 
the time of onset of symptoms resulting in hospital presenta- 
tion. Time of hospital arrival and time of thromboiysis (initi- 
&on of infusion) were obtained from hospital records. 
Before publication of thii manuscript, an extensive quality- 
controi etrort was completed that resulted in some changes in 
the data published in the initial report of GUSTO-I (14-16). 
In the original pubiicatkq for missing data on the time of 
symptom onset, an estimate made by the diician during 
randomiz&n was used. After completion of case report 
formsandariauditoflZ%ofthesefomrsagaimtsourcc 
doaunentati, in addition to q&matic che& at the Coor- 
dinating Center, iiumcrous Corrcction~ hjd been made in the 
i&ii data. The final quali&controUd infowatiw retkcts 
tbefoUowingehan~timetotreatimentchaqcdffommising 
to complete in 4,757 patients. .rom complete to mMing in 21 
patients and to an earlier or later interval in 41 patiena A 
detailed summary of these changes is shoa-n in Tabk 1. 
stetist*rl ita+&. IA2bptke statistii (percentages for 
discrete variabkx medians with 25th and 75th percentib fen 
continuous m) were generated for basline characteris- 
tics and events for all time-to-treatment *ariabks Far ar&v& 
each time-to-treatment variahk was prosp&vely dixided into 
four intervals. Lkcause of the large size of the data base end to 
avoid confti as to theii interpretation. ue do not prexnt p 
mhtes. 
We investigated the relations of enrollment site (United 
States or non-United States) and bayline characteistics to 
overail time to treatment and presentation and trcatmcnf 
deliqs. Outcomes irJeyed in relation to time variM uere 
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4.8 (3.b, 5.3) 
II3 (75, ?US) 
M-day and in-h<npital mortality, srrokr \&types, reinfatction, 
recurrent itihemta. shock. and congey(ne heart failure and the 
combined end pomtu 01 death or \trokc. deurh or primary 
intracranirl hemorrhage and death or disabling ~lroke. 
Results 
Time ta treatment. Complctc data for time from qmptom 
onset 10 thrornboiysis were available for 39.KG of the JI,K!I 
patients tU7.15 ). C’umulalive dLributions of rime Lo treat. 
mcnt overall and by enrollment site (Uniled Slatir versus 
nonJ.~m~ed SMCS) are shown in f:igure I. Overall time to 
trcatn cnl was -- 4 h in 77.4% of patients; most of the rest were 
lreiiled between 4 and 6 b &iy 26.6% of patients were IrCdtCd 
uithin 2 h of symptom onset. 
Riixline characlerlstics by time from stziptom onset to 
treatment are shown in Table 2. Female, hypertensive. and 
cbabetic patients were found in greater proportions in tile 
later-treated group, and current or former cigarette .srnoken 
werr more often in ibe earlier-treated groups. Prior myoma:. 
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Table 3. Time From Symptom Onset ta Treatment: Clinical Events 
52 h ~2-4 h >4-6 h >6h 
(n = lU,611) (n = 33.213) (n = 7,650) (n = !M9) .-- ---- 
ln~hospital mortality 5.3 5.9 85 8.9 
W di9 5.s 6.3 9.0 9.0 
stroke 1.3 1.5 1.6 2.0 
Primmy intracranial 0.5 u.7 0.8 LO 
hmnnhsgc 
uoahemonhagic 0.6 0.6 0.7 1.u 
HeUlO~ 7.1 U.I 0.1 0 
conversion 
Unknown 0.1 0. I 0.1 u 
Death or atrokc 6.2 7.1 9.8 10.2 
Death OT 5.7 6.5 9.2 9.4 
hemorrhagic stroke 
Death or disabling 6.0 6.7 9s Y.6 
stmke 
Reinfaretlnn 4.7 4.0 3.2 3.6 
Recurrent isehemir 21 2u IV I8 
Shock 5.7 5.6 6.4 70 
Congestive heart fsilurc I4 I6 19 I9 
Data presented are percent of patienu. 
g 0.02 I 
0 2 4 0 8 
Thno from symptom OIlsof 1” Trestrnolu 
(houW 
Pittme 3. Probability of 3May mortality as a hmction af time from 
symprom omen to treatment and assigament to streptolinase with 
rubnrtaneous beparin tstuut dasbts). atreptukinasc with inuavea~ 
heparin (t&M so&t liar), streptoldnsse aad tissue-type PbuaWgen 
activator (t-PA) with intravenous bepaM (hmgdasbss) or aaelerated 
I-PA with intravenous heparin Iline with ). The pmbability 
for the combined streptekinase gruups is show0 by tbe bemy solid hue 
dial infarction was more frequent in the later-treated groups, 
and patients treated after 2 h were older, weighca less, had 
higher systolic blood pressures and heart rates and were more 
likely to be nonwhite and to have congestive hedrl failure 
(Killip class 41). Other than a slight delay (median 5 mm) in 
patients treated with combination thromholytic therapy, there 
were no differences in time to treatment as a function of 
treatment assignment. 
strategy as a function of time from symptom onset to treat- 
ment. Although the relative treatment effect was slightly 
greater for patients treated earlier, the formal test for time-to- 
treatment interaction for t-PA versus !he combined streptoki- 
nase groups was not significant (p = 0.38). 
Table 3 shows the relations between time to treatment and 
selected clinical end points. As time to treatment increased, 
3O-day mortality increased (Fig. 2). The incidence of stroke 
also increased as time to treatment increased, mostly through 
an increase in primary intracranial hemorrhage. Reinfarction 
and recurrent ischemia were less frequent, and the incidence of 
shock and congestive heart failure greater, as time to treatment 
increased. 
Presmtatiuu delay. Cumulative distributions of time horn 
symptom onse; to hospital arrival are shown in Figure 4. 
Patients enrolled m the United States arrived earlier than 
patients elsewhere (median 85 vs. 105 mm). Overall, most 
patients arrived within 2 h of symptom onset. 
Relations between presentation delay and baseline ~harac- 
teristics are shown in Table 4. The distribution of baseline 
characteristics was similar to that for the total-time-to- 
treatment group. However, patients with a family history of 
Figure 3 shows treatment benefit of each thrombolytic 
hpre 2. Probao~l~~~ (solid line) and 95% confidence intcr;& 
(dashed lines) for 3May mortality as a function of time to treatment. 
Fi@am 4. Cumulative distribution of time from symptom onset to 
hcspi!ai arrk! board! holid Soa) and for patients enrolled in the 
United States (brig da&a) verws outside the United States (short 
daSkSL 
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coronary artery discare or with ;I previous infarcttan p::-xntcd 
eurlicr, where:tc those with previous angina alone preserrkd 
later. ‘There was no relationship between present&on delay 
end ethnicity. 
Chrtcomcs a\ :I function of timr to pre.wnt;rtion (Txhlr ?) 
gcncrally mirrorctl tho\c ol thr ovrridl tirnu.to-trcntrncrlt 
group rnidyai~. 
r’rertmrat d&y. Figure 5 presents cumulative distrihu- 
tions of time from hf.qital arrival to trP;ltment. Non-IJnited 
States patients had a slightly .h:::rr :reatmcnt de!sy !han U.S. 
patients (median bo vx M min). Only 43% of patients were 
ttcrted within m hour of anival. 
Tahlc b shows the I)ascline ch;i.acteristicz for each treat- 
ment delay category. For most variables. the associations were 
similar IO those for total time lo tr:;ltment and prcscntution 
d&y. However, patients with prior hypas su~$cry or angina 
W longer trratmcnt dcltiys, us did hi& iurd other nonwhite 
pittienl$ Thox with ti lumily history of coronary urtcry disease 
or a prror infarction had longer treatment drh~ya. even though 
they prcsqted ,sooncr. 
Patients with longer treatment delays had more advers*: 
outcomes such as death, stroh, shock ,md hrprt fAure (Tahlc 
7). As with the other delay times. reinfarkon YZ. less common 
in patknts wiih a lunger treatment delay. 
JACC Vol. 27, No. 7 NEWBY ETAL. 
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Tabk 5. Time From Symptom 0nse1 to Hospital Arrival: Clinical Events 
--- 
<1 h l-2 h J-4 h >4 h 
(n - 9375) (a = 14308) (n Q 11441) (n = wa 
In-hospital mortatity 5.3 5.9 7.2 85 
MY mty 5.6 62 7.6 8.6 
Stmke 1.4 1.4 1.5 I.8 
Primmy imneminl hemonhage 0.65 0.61 0.6% 01 
Nonhemoti8gte 0.59 058 054 0.73 
Hemmhagic conversion 0.08 0.07 0.11 0.04 
Unh 0.08 0.14 0.17 ml 
De801 or amkc 6.4 7.0 Il.4 9.8 
Death or hemorrhagic stroke 5.9 6.5 7.8 9.1 
Death tb dirsbling stmkc b.l 6.7 11.1 9.2 
Reinfuclion 3.7 4.0 3.7 3.4 
Recurrem ischemia 21 20 IQ 17 
Shock 5.6 6.0 5.7 b.7 
Congestive heat failure I5 16 17 I9 
Dkcussion 
This evaluation of the 41,021 GUSTO-I patients shows that 
substantial differences in baseline characteristics and outcomes 
exist between patients who pursue and receive thrombolysis 
promptly and those whose treaunent is delayed. Further, 
although a trend is present, the relative reduction in mortality 
from accelerated t-PA treatment is not signitkantiy a&ted by 
this delay. Most characteristics associated with longer presen- 
tation delay are also associated with longer treatment delay, 
raising the possibility that focusing attention on female, el- 
derly, diabetic and more critically il l patients can greatly 
improve outcomes by reducing time to treatment. 
Time to treatment. Defined as time from symptom onset to 
initiation of infusion, !ime to treamlent provides an estimate of 
the total time of vessel occlusion. Accurate assessment of 
treatment effect as a function of time is ditlicult, however, 
because the measurement of time to treatment is inherently 
imprecise; time of symptom onset and time of thrombtrbtic 
Flgwa 5. Cumulative distribution of time frwn hospital arrival to 
treatment overall (s&l Hne) and for patients enrolkd in the United 
States (tuq dart& and ouaide the United States (short &she@. 
initiation do not correlate exactly with the relevant events- 
vessel occlusion und reperfusi&, respectively. Further, the 
variable time to treatment does not capture the additional time 
from thrombolytic initiation to reperfusii nor is infarct- 
artery patency achieved in each case. Indeed, when w 
reperfusiin oszurs 45 to 60 min after initiation of tluombolytic 
therapy (17.18). 
In GUSTO-I, the median time to treatment was 2.8 h, 
similar to that seen in actual practice (median 2.75 h) during 
the sane time period, as suggested by comparkm with data 
from the National Registry of Myocardii Infarction (NRMI) 
survey (19). To better assem risk factors for this delav in 
treatment, we prospe&eiy divided overall delay into two 
components: presentation delay, which reikcts patient-related 
delays, and treatment delay, which rekcts the response of 
hospitals to patients. 
l3wenUon a’day. Studies show that presentation delay 
accounts for the greater proportion o! total time to treatment 
(20,21). The median presentation delay in GUSTO-l was 92 
minutes, 55% of total time to treatment. Studies suwt that 
patients tak.e much of this time to decide to xeit medical 
treatment f 13,20-24). Many facton have been shown to alfect 
this decision, including time of day, day of the week, location 
of the patient when symptoms occur, symptom severity or 
typicality and whether advice is sought from co-workem, family 
members or the family physiian (13,X23,25-27). 
Our analysis, based on over 41,000 patients, adds substan- 
tial information and clarification to smaller. less detailed 
0bwations (13,1tU&2829). It supports the fin+ng that 
advanced age, diabetes, hypertension and prior angina are 
indeed risk factors for presentation delay, as is female gender. 
Contrary to pmvious stud& we noted an association between 
earlier presentation and prior infarction or family history Of 
coronary dii. Further. there WBS no relation of race to 
presentation delay. Ahbough median bkmd pressure was iower 
in the groups presentis@ earlier, other marken of a compli- 
cated infarction-faster heart rate and higher Killip class- 
1652 NEWBY ET AL. JACC Vol. 27. No. 7 
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Table 6. Time From Hospital Arrival tu Trwtmcnt; Bwline Characteristic\ 
-..^- _ .-,-.- - ---, I-- ----.- -- 
z3U min 30-60 min 
(n * 2,728) (Il = 13.4u3) 




















































72(6l.K5) 7.1(63. X6) 
IZY (112,144) 130(113.144) 
80 (70,yo) nu (70, YIJ) 
7s ((4%) 
lW(113.144) 












H(S,l3) 7(4,I2) bPl.ll) 
4 (3.6) 4 (3.5) 4 (3,s) 
3 (2.4) 3 (2.41 2(1.3) 
0.6 U.7 I.2 
3.4 3.4 3.x 
3.4 4.x 4.4 
0.1 U.I U.2 
1.5 (1.0,2.5) 1.5 (lU, 2.5) l.S(l.U.2.4) 
fd)-W min AU mm 
(II = 11.246) (ll -: 10.227) 
Data prevnted or’: pcrcenr of patients or median (2.%n. 75th percmtile$ Ahhrcvirtiuns a in ‘Table 2. 
were associated with longer prewntalion dcluy in GUSTO-I. 
Table 8 bumrnatizcs Ihcse comparisons. 
Trrtr~cnr Crclq In GUSTO~I, the median rrcatment delay 
was 64 min. Little information exists regarding the relation of 
baseline characteriprics to treatment delay. One study Cd show 
that the degree of ST segment deviallon on irtitial clecttocat- 
diograpby wa importint (30). In out study, most chatsctct~~ 
tics asmiated with longer presentation delay were also as* 
ctlrtrd with longer treatment &lay. Nonwh me race was 
assuciatcd +I& with longer treatment &lay <,:,), ~texWtii+l 
del.*y). la addition, pnot bypa~ surgery end previous infarc- 
tion, whir.n were tiated with no etiect on and Wet 
prcscntation delays. respectively, were associated with longer 
treatment delay. Groups with longer treatment delays were 
those whose initial symptoms are mote likely atypical (women, 
diabetics, the elderly) or for whom the benefit relative to the 
risks of thtombolysis ate uncertain (the elderly, hypertensive+ 
Although differences existed in the distribution of electtocat- 
diogtaphic variables (othct than infarct location) hctwecn 
earlier- and later-treated patients, these were small and un- 
likely to be of major clinical significance (Tabks 2.4 and 6). 
Time to treatwst-trportmce d tieby to dlnlcal wit- 
camea. The Fibrinolyiic Therapy Trial&s’ meta-analysii su8 
ge5ted that outcome was significantly better with shorlct time 
JAC(‘ Vol. 27, No. 7 NbWHY El AL. 1653 June 1996:1646-55 EFFtm OF TIME TO TifRDMtlf>LYSIS 
Table 9. Time From Hospital Arrival to Treatment: Clinical E~~enth 
-I- -- 
q: 30 mill 30-Ml min f&W min 
(ll .- 2.728) (II * 13.403) (II * 11.246) ~ ---- -..-- ..--.. -L-I --.- I_ 
In-htqirnl morMy 5.4 5.1 6.1 
304ay monulity 54 54 6.4 
Broke I.0 1.3 I4 
Primnry intwranial hemorrhage 0.4 0.h 0.7 
Nonhenwrhagic 0.4 0.5 0.7 
Hcmwrhagic crmversion~ 0.04 007 0.11 
Unknown 0.1 0.2 0. I 
Denth nr swokc 5.Y h.? 7.3 
Deirlh or hemonhngic woke 5.0 S.h h.7 
Dwlh or disabling rwokc 5.n 5.0 6.9 
Rein&rSIUnl 41 4.2 3.7 
Rwrrcm wlwniil Ih IY ?I1 
Slwk 5.1 5.7 6.0 
Congcsrive heart fdnre I3 I5 Ih 
:40 win 















Datn prwnrrd UC pcrccni of paGents. 
from symptom onset (I.6 additional lives saved per I.000 
treated for each hour earlier that tteatmenl began) (I). The 
absolute and relative treatment effects for therapy 1 h earlier 
were greater the earlier treatment began, presumably reflect- 
ing the important time-dependent effect of vessel occlusion on 
the extent of irreversible myocardial damage. Similarly in 
GUSTO-I, independent of thrombolytic assignment, delays at 
any point adversely affected mortality and the development of 
heart failure or shock. underscoring the importance of early 
recognition of and response to ischemic symptoms. Although 
stroke, mostly hemorrhagic, seemed to increase with increased 
time to treatment, a multivariable analysis of stroke risk factors 
in GUSTO-I found no relation with time to treatment (31). 
Overall mortality increased as time to treatment increased, 
but patients treated very early (Cl h) after symptom onset 
T&e 8. Association of Eiascliw Characteristics With Presentation 
Delay: Compnriwn of Prcwus Reports With GUSTO-I 
appeared to have higher mortality than those treated between 
l-;nd 3 h (Fig. 2). It may be that patients who present and are 
treated very early are sieker, with a higher expected mortality. 
The small number of patients treated within I h may have 
limited the ability to detect a difference in severity of illness 
between these groups. Further, patients with acute myocardial 
infarction have the greatest risk of lethal ventricular arrhyth- 
mias during the first hour of symptoms. Perhapr the higher 
mortality observed in patients with a shorter time to throm- 
bolysis simply reflects this pathophysiology. Finally, the smell 
size of the group treated within I h and the wide 95% 
contidcnce intervals suggest that caution should be used in 
interpreting tkese results. 
&cause presentation delay primarily reflects patient re- 
sponse to symptoms. public education programs have been the 
main focus for its improvement. To date, mass-media cam- 
paigns and public education programs have had variable 
results in improving presentation delay (32-35). Programs and 
services focused on groups idendtied as being at highest risk 
for presentation delay may be mare helpful. 
Because it reflects the medical system reapon% to patients, 
time to treatment may be most easily decreased through 
procedurai and diagnostic strategies focused on treatment 
delay. Institution of specific emergency room protocols can 
significantly reduce treatment <clay (2X36-31). as can admin- 
istration of thrombolysis by emergency room physicians with- 
out mandatory cardiology consultation (25). arrival by ambu- 
lance (22) and transmission of an initial electrocardiogram 
from the ficld (39.40). 
Tlme lo tmlnsesldtalefl L-P.4 vcIM)s Olrrpkokll4n~* 
The GUSTO-1 investigaton postulated that more rapid repet- 
fusion with accrlerated t-PA would result in proportionately 
more mytrcardial salvage in patients treated early and would be 
reflected& a greater survival advantage in these patients. The 
original G!‘STO-I report noted an apparent interaction be- 
twecn earlier treatment with accelerated t-PA and a yeater 
relative \urvivrl benefit (11). However, after careful quality- 
1654 NEWBY FX AL 
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control measures, the trend toward a greater survival benctil 
with accclcrated I-PA in patients treated early did not reach 
statistical significance (15.16). This result may emanate from 
hvo major factors: the timing of symptom onset is not precisely 
related to the initial coronary occlusion, and hecause patients 
with longer times to treatment are generally sicker (with a 
higher expected mortality), they therefore have a greater 
mathematical opportunity for clinical benefit, although patho- 
physiologically their chances for benefit are less. Several 
statistical issues regarding thii finding also must be addressed. 
Fit, because the analysts for treatment interaction uses time 
to treatment as a continuous variable, the relatively few (4,825) 
changes in data that resulted from the quality-control process, 
although not altering the shape of the data, were sufficient in 
this setting to change a borderline statistically significant result 
(p - 0.04) to a, nonsignificant one (p = 0.38). Further, for the 
comparison of t-PA versus the combined streptokinase stratc- 
gies, post hoc analysis shows that the power of the test for an 
interaction of treatment effect with time to treatment is only 
about 0.18. However, with a sample si-e of river 40,000 patients 
for the overall analysis, the p value ot 0.38 Indicates strong 
evidence of no differential effect rather than a lack of power to 
detect a difference. Although the relative benefit from t-PA in 
the first hour seems greater, as does that for the combination 
therapy after 5 h, the number of patients in each group at these 
intervals was small, precluding any definitive statements about 
these observations. 
Concbtsians. Although imprecision in measurement may 
limit our ability to detect subtle time-dependent treatment 
ekcts somewhat, we found no additional relative advantage 
for earlier treatment with accelerated t-PA versus streptoki- 
nase, although a trend was present. Regardless of the agent, 
earlier thrombolysis resulted in better outcomes, with the best 
effects for treatment within 2 h of symptom onset. Focused 
educational, diagnostic and management strategies to facilitate 
early identification and rapid treatment, especially of those at 
high risk for delay, should help maximire the benefits of 
thmmbolytic therapy. 
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